Up-regulation of AMP-activated kinase by dysfunctional cystic fibrosis transmembrane conductance regulator in cystic fibrosis airway epithelial cells mitigates excessive inflammation

Kenneth R. Hallows, Adam C. Fitch, Christine A. Richardson, Paul R. Reynolds, John P. Clancy, Pierre Dagher, Lee A. Witters, Jay K. Kolls, Joseph M. Pilewski

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

AMP-activated kinase (AMPK) is a ubiquitous metabolic sensor that inhibits the cystic fibrosis (CF) transmembrane conductance regulator (CFTR). To determine whether CFTR reciprocally regulates AMPK function in airway epithelia and whether such regulation is involved in lung inflammation, AMPK localization, expression, and activity and cellular metabolic profiles were compared as a function of CFTR status in CF and non-CF primary human bronchial epithelial (HBE) cells. As compared with non-CF HBE cells, CF cells had greater and more diffuse AMPK staining and had greater AMPK activity than their morphologically matched non-CF counterparts. The cellular [AMP]/[ATP] ratio was higher in undifferentiated than in differentiated non-CF cells, which correlated with AMPK activity under these conditions. However, this nucleotide ratio did not predict AMPK activity in differentiating CF cells. Inhibiting channel activity in non-CF cells did not affect AMPK activity or metabolic status, but expressing functional CFTR in CF cells reduced AMPK activity without affecting cellular [AMP]/[ATP]. Therefore, lack of functional CFTR expression and not loss of channel activity in CF cells appears to up-regulate AMPK activity in CF HBE cells, presumably through non-metabolic effects on upstream regulatory pathways. Compared with wild-type CFTR-expressing immortalized CF bronchial epithelial (CFBE) cells, ΔF508-CFTR-expressing CFBE cells had greater AMPK activity and greater secretion of tumor necrosis factor-α and the interleukins IL-6 and IL-8. Further pharmacologic AMPK activation inhibited inflammatory mediator secretion in both wild type- and ΔF508-expressing cells, suggesting that AMPK activation in CF airway cells is an adaptive response that reduces inflammation. We propose that therapies to activate AMPK in the CF airway may be beneficial in reducing excessive airway inflammation, amajor cause of CF morbidity.

Original languageEnglish
Pages (from-to)4231-4241
Number of pages11
JournalJournal of Biological Chemistry
Volume281
Issue number7
DOIs
StatePublished - Feb 17 2006

Fingerprint

Cystic Fibrosis Transmembrane Conductance Regulator
AMP-Activated Protein Kinases
Cystic Fibrosis
Up-Regulation
Epithelial Cells
Inflammation
Fibrosis
Adenosine Monophosphate
Interleukin-6
Adenosine Triphosphate
Chemical activation
Metabolome
Interleukins
Interleukin-8

ASJC Scopus subject areas

  • Biochemistry

Cite this

Up-regulation of AMP-activated kinase by dysfunctional cystic fibrosis transmembrane conductance regulator in cystic fibrosis airway epithelial cells mitigates excessive inflammation. / Hallows, Kenneth R.; Fitch, Adam C.; Richardson, Christine A.; Reynolds, Paul R.; Clancy, John P.; Dagher, Pierre; Witters, Lee A.; Kolls, Jay K.; Pilewski, Joseph M.

In: Journal of Biological Chemistry, Vol. 281, No. 7, 17.02.2006, p. 4231-4241.

Research output: Contribution to journalArticle

Hallows, Kenneth R. ; Fitch, Adam C. ; Richardson, Christine A. ; Reynolds, Paul R. ; Clancy, John P. ; Dagher, Pierre ; Witters, Lee A. ; Kolls, Jay K. ; Pilewski, Joseph M. / Up-regulation of AMP-activated kinase by dysfunctional cystic fibrosis transmembrane conductance regulator in cystic fibrosis airway epithelial cells mitigates excessive inflammation. In: Journal of Biological Chemistry. 2006 ; Vol. 281, No. 7. pp. 4231-4241.
@article{31908b761c0847eab60e5c104941da4f,
title = "Up-regulation of AMP-activated kinase by dysfunctional cystic fibrosis transmembrane conductance regulator in cystic fibrosis airway epithelial cells mitigates excessive inflammation",
abstract = "AMP-activated kinase (AMPK) is a ubiquitous metabolic sensor that inhibits the cystic fibrosis (CF) transmembrane conductance regulator (CFTR). To determine whether CFTR reciprocally regulates AMPK function in airway epithelia and whether such regulation is involved in lung inflammation, AMPK localization, expression, and activity and cellular metabolic profiles were compared as a function of CFTR status in CF and non-CF primary human bronchial epithelial (HBE) cells. As compared with non-CF HBE cells, CF cells had greater and more diffuse AMPK staining and had greater AMPK activity than their morphologically matched non-CF counterparts. The cellular [AMP]/[ATP] ratio was higher in undifferentiated than in differentiated non-CF cells, which correlated with AMPK activity under these conditions. However, this nucleotide ratio did not predict AMPK activity in differentiating CF cells. Inhibiting channel activity in non-CF cells did not affect AMPK activity or metabolic status, but expressing functional CFTR in CF cells reduced AMPK activity without affecting cellular [AMP]/[ATP]. Therefore, lack of functional CFTR expression and not loss of channel activity in CF cells appears to up-regulate AMPK activity in CF HBE cells, presumably through non-metabolic effects on upstream regulatory pathways. Compared with wild-type CFTR-expressing immortalized CF bronchial epithelial (CFBE) cells, ΔF508-CFTR-expressing CFBE cells had greater AMPK activity and greater secretion of tumor necrosis factor-α and the interleukins IL-6 and IL-8. Further pharmacologic AMPK activation inhibited inflammatory mediator secretion in both wild type- and ΔF508-expressing cells, suggesting that AMPK activation in CF airway cells is an adaptive response that reduces inflammation. We propose that therapies to activate AMPK in the CF airway may be beneficial in reducing excessive airway inflammation, amajor cause of CF morbidity.",
author = "Hallows, {Kenneth R.} and Fitch, {Adam C.} and Richardson, {Christine A.} and Reynolds, {Paul R.} and Clancy, {John P.} and Pierre Dagher and Witters, {Lee A.} and Kolls, {Jay K.} and Pilewski, {Joseph M.}",
year = "2006",
month = "2",
day = "17",
doi = "10.1074/jbc.M511029200",
language = "English",
volume = "281",
pages = "4231--4241",
journal = "Journal of Biological Chemistry",
issn = "0021-9258",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "7",

}

TY - JOUR

T1 - Up-regulation of AMP-activated kinase by dysfunctional cystic fibrosis transmembrane conductance regulator in cystic fibrosis airway epithelial cells mitigates excessive inflammation

AU - Hallows, Kenneth R.

AU - Fitch, Adam C.

AU - Richardson, Christine A.

AU - Reynolds, Paul R.

AU - Clancy, John P.

AU - Dagher, Pierre

AU - Witters, Lee A.

AU - Kolls, Jay K.

AU - Pilewski, Joseph M.

PY - 2006/2/17

Y1 - 2006/2/17

N2 - AMP-activated kinase (AMPK) is a ubiquitous metabolic sensor that inhibits the cystic fibrosis (CF) transmembrane conductance regulator (CFTR). To determine whether CFTR reciprocally regulates AMPK function in airway epithelia and whether such regulation is involved in lung inflammation, AMPK localization, expression, and activity and cellular metabolic profiles were compared as a function of CFTR status in CF and non-CF primary human bronchial epithelial (HBE) cells. As compared with non-CF HBE cells, CF cells had greater and more diffuse AMPK staining and had greater AMPK activity than their morphologically matched non-CF counterparts. The cellular [AMP]/[ATP] ratio was higher in undifferentiated than in differentiated non-CF cells, which correlated with AMPK activity under these conditions. However, this nucleotide ratio did not predict AMPK activity in differentiating CF cells. Inhibiting channel activity in non-CF cells did not affect AMPK activity or metabolic status, but expressing functional CFTR in CF cells reduced AMPK activity without affecting cellular [AMP]/[ATP]. Therefore, lack of functional CFTR expression and not loss of channel activity in CF cells appears to up-regulate AMPK activity in CF HBE cells, presumably through non-metabolic effects on upstream regulatory pathways. Compared with wild-type CFTR-expressing immortalized CF bronchial epithelial (CFBE) cells, ΔF508-CFTR-expressing CFBE cells had greater AMPK activity and greater secretion of tumor necrosis factor-α and the interleukins IL-6 and IL-8. Further pharmacologic AMPK activation inhibited inflammatory mediator secretion in both wild type- and ΔF508-expressing cells, suggesting that AMPK activation in CF airway cells is an adaptive response that reduces inflammation. We propose that therapies to activate AMPK in the CF airway may be beneficial in reducing excessive airway inflammation, amajor cause of CF morbidity.

AB - AMP-activated kinase (AMPK) is a ubiquitous metabolic sensor that inhibits the cystic fibrosis (CF) transmembrane conductance regulator (CFTR). To determine whether CFTR reciprocally regulates AMPK function in airway epithelia and whether such regulation is involved in lung inflammation, AMPK localization, expression, and activity and cellular metabolic profiles were compared as a function of CFTR status in CF and non-CF primary human bronchial epithelial (HBE) cells. As compared with non-CF HBE cells, CF cells had greater and more diffuse AMPK staining and had greater AMPK activity than their morphologically matched non-CF counterparts. The cellular [AMP]/[ATP] ratio was higher in undifferentiated than in differentiated non-CF cells, which correlated with AMPK activity under these conditions. However, this nucleotide ratio did not predict AMPK activity in differentiating CF cells. Inhibiting channel activity in non-CF cells did not affect AMPK activity or metabolic status, but expressing functional CFTR in CF cells reduced AMPK activity without affecting cellular [AMP]/[ATP]. Therefore, lack of functional CFTR expression and not loss of channel activity in CF cells appears to up-regulate AMPK activity in CF HBE cells, presumably through non-metabolic effects on upstream regulatory pathways. Compared with wild-type CFTR-expressing immortalized CF bronchial epithelial (CFBE) cells, ΔF508-CFTR-expressing CFBE cells had greater AMPK activity and greater secretion of tumor necrosis factor-α and the interleukins IL-6 and IL-8. Further pharmacologic AMPK activation inhibited inflammatory mediator secretion in both wild type- and ΔF508-expressing cells, suggesting that AMPK activation in CF airway cells is an adaptive response that reduces inflammation. We propose that therapies to activate AMPK in the CF airway may be beneficial in reducing excessive airway inflammation, amajor cause of CF morbidity.

UR - http://www.scopus.com/inward/record.url?scp=33645231670&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645231670&partnerID=8YFLogxK

U2 - 10.1074/jbc.M511029200

DO - 10.1074/jbc.M511029200

M3 - Article

C2 - 16361706

AN - SCOPUS:33645231670

VL - 281

SP - 4231

EP - 4241

JO - Journal of Biological Chemistry

JF - Journal of Biological Chemistry

SN - 0021-9258

IS - 7

ER -